Clinical Trial Detail

NCT ID NCT03848754
Title Pracinostat in Combination With Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Medical College of Wisconsin
Indications

acute myeloid leukemia

Therapies

Gemtuzumab ozogamicin + Pracinostat

Age Groups: adult senior

No variant requirements are available.